Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Product
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Xerostomia Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Xerostomia Therapeutics Market Analysis Tools
3.4.1. Industry analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Xerostomia Therapeutics: Type Estimates & Trend Analysis
4.1. Xerostomia Therapeutics Market: Key Takeaways
4.2. Xerostomia Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Over-the-counter (OTC)
4.3.1. Over-the-counter (OTC) market estimates and forecast 2018 to 2030 (USD million)
4.4. Prescription
4.4.1. Prescription market estimates and forecast 2018 to 2030 (USD million)
Chapter 5. Xerostomia Therapeutics: Product Estimates & Trend Analysis
5.1. Xerostomia Therapeutics Market: Key Takeaways
5.2. Xerostomia Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Salivary Stimulants
5.3.1. Salivary stimulants market estimates and forecast 2018 to 2030 (USD million)
5.4. Salivary Substitutes
5.4.1. Salivary substitutes market estimates and forecast 2018 to 2030 (USD Million)
5.5. Dentifrices
5.5.1. Dentifrices market estimates and forecast 2018 to 2030 (USD million)
Chapter 6. Xerostomia Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Xerostomia Therapeutics System Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. China
6.5.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.2. Japan
6.5.2.1. Market estimates and forecast, 2018 – 2030 (Volume, Thousand)
6.5.3. India
6.5.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Acacia Pharma
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Type benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Parnell Pharmaceuticals, Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Type benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Pfizer, Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Type benchmarking
7.2.3.4. Strategic initiatives
7.2.4. GlaxoSmithKline plc
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Type benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Church & Dwight Co., Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Type benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Lupin
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Type benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Sun Pharmaceutical Industries, Ltd.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Type benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Hikma Pharmaceuticals PLC
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Type benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Pendopharm
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Type benchmarking
7.2.9.4. Strategic initiatives
7.2.10. OraCoat
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Type benchmarking
7.2.10.4. Strategic initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer